Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Biogen Australia Pty Ltd

 COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

Sections 14 and 14A Notice

On 9 December 2015, a delegate of the Secretary of the Department of Health, on the application of Biogen Australia Pty Ltd, consented under sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) to the supply of

• interferon beta-1a (rch) (AVONEX) 30 mcg (6MIU) powder for injection vial (attached Bioset device) with diluent syringe composite pack [AUST R 79752]
• interferon beta-1a (rch) (AVONEX) 30 microgram/0.5 mL injection pre-filled syringe             [AUST R 95419]
• interferon beta-1a (AVONEX PEN ) 30 microgram / 0.5 mL solution for injection prefilled pen [AUST R 180136]

that do not conform with the requirements of paragraph 3(2)(l)of the Therapeutic Goods Order No 69 – General requirements for labels for medicines , in that the sponsor’s old street address (for all batches given in Table 1) will be on the product labels until such time as labels with the revised sponsor address are approved by the Therapeutics Goods Administration and implemented in the supply chain.

Table 1: List of batches with sponsor’s old street address (Suite 1, Level 5, 123 Epping Road North Ryde) on the labels:

In addition to the above, you also asked for the Secretary’s consent to supply the products in Australia notwithstanding they do not conform with the requirements of the paragraph 3(2)(l)of the Therapeutic Goods Order No 69 – General requirements for labels for medicines in that the sponsor’s old name ( for batches listed in Table 2) will be on the product labels to facilitate inventory management associated with the changes in both sponsor name and sponsor address.

Table 2: List of batches with sponsor’s old name (Biogen Idec Australia Pty Ltd) on the labels:

The consent is effective from 9 December 2015 until 24 June 2017.

The consent is subject to the following conditions:

1. This consent applies to those batches (listed in Table 1) that are warehoused in Australia, those already produced, labelled and packed for Australia and held in overseas warehousing, or those currently in production for Australia.
2. For batches of products listed in Tables 1 and 2 other sponsor’s valid contact information such as telephone and postal address details will remain the same.
3. The new office location is clearly signposted within the building and postal communications are being received at the new office.
4. The sponsor will submit changes to labels and product information for approval under section 9D of the Act to reflect the revised sponsor’s name and address.